A Phase 3 interventional study of Orforglipron and Dapagliflozin in Type 2 Diabetes, sponsored by Eli Lilly and Company. Completed at 74 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-16.
Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies testing orforglipron in Diabetes Mellitus, Type 2 — 3 open to participants now, 5 under way, 4 of them phase 3. orforglipron · Diabetes Mellitus, Type 2.
Among the 15 studies testing orforglipron in Diabetes Mellitus, Type 2, this one is the 5th largest by enrollment, is the only one that started in 2024, is one of 11 in phase 3, and was the 10th registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →3 of the 15 studies testing orforglipron in Diabetes Mellitus, Type 2 are open now, in 12 countries. Recruiting first, the newest first:
Eli Lilly and Company · Sites in India, Saudi Arabia, South Africa and 1 more country
Ages 18–65
Eli Lilly and Company · Sites in United States, Belgium, Brazil and 8 more countries
Ages 10–17
Massachusetts General Hospital
Ages 18–79
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, orforglipron is the treatment under test here. Read study by study →
15 studies; the count open now beside each. This study's row is marked.
First in 2020; this study’s year is marked. 1 started in 2024.
This study's enrollment of 962 is above the median of 80 across 8,359 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 546 across the 15 interventional studies. Of the 10 that completed or were terminated, 9 (90%) have results posted.
This tab as a report to print or save as PDF → With an account.
14 of 15 have an industry lead sponsor. The 2 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
238 studies in Diabetes Mellitus, Type 2 by Eli Lilly and Company: 10 open now, 21 under way, 11 of them phase 3. Of 211 finished, 155 (73%) have results posted.
Among the 238 studies in Diabetes Mellitus, Type 2 by Eli Lilly and Company, this one is the 27th largest by enrollment of the 232 interventional ones that give a count, is one of 9 that started in 2024, is one of 85 in phase 3, and was the 207th registered.
Eli Lilly and Company’s Diabetes Mellitus, Type 2 studies by the year they started, since 2001.
3 of the studies testing orforglipron in Diabetes Mellitus, Type 2 that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07613307Phase 3Eli Lilly and CompanyA Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes Who Observe Ramadan Fasting | 2027-05 |
| NCT06993792Phase 3Eli Lilly and CompanyA Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes | 2027-08 |
| NCT06972472Phase 3Eli Lilly and CompanyA Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes | 2027-08 |
Add all 3 to your calendar (.ics) → With an account.
Among the 15 studies testing orforglipron in Diabetes Mellitus, Type 2, from their registry updates:
Among Eli Lilly and Company’s 238 in Diabetes Mellitus, Type 2:
This tab as a report to print or save as PDF → With an account.
The main purpose of this study is to assess the safety and efficacy of orforglipron compared with dapagliflozin in improving blood sugar control in participants with type 2 diabetes (T2D) with inadequate glycemic control using metformin. The study will last approximately 46 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received orforglipron, administered orally once daily (QD), starting at a dose of 1 milligram (mg) and escalated at week 4 to a dose of 3 mg, which was then maintained up to week 40.
Drug: Orforglipron
Participants received orforglipron, administered orally QD, starting at a dose of 1 mg and escalated every 4 weeks (to 3 mg at week 4 and 6 mg at week 8) until reaching a dose of 12 mg at week 12, which was then maintained up to week 40.
Drug: Orforglipron
Participants received orforglipron, administered orally QD, starting at a dose of 1 mg and escalated every 4 weeks (to 3 mg at week 4, 6 mg at week 8, 12 mg at week 12, and 24 mg at week 16) until reaching a dose of 36 mg at week 20, which was then maintained up to week 40.
Drug: Orforglipron
Participants received dapagliflozin, administered orally QD, at a fixed dose of 10 mg starting at randomization, which was maintained up to week 40.
Drug: Dapagliflozin
Administered orally
Also known as: LY3502970
Administered orally
Change From Baseline in HbA1c [Noninferiority Analysis]
* Hemoglobin A1c (HbA1c) is the glycosylated fraction of hemoglobin A, measured to reflect average plasma glucose concentration over a prolonged period of time. * Values represented under "Least Squares (LS) Mean" are model-based estimates (MBE) of the unconditional average treatment effect. MBE were calculated using a mixed-model repeated measures (MMRM) analysis for post-baseline measures, with country, baseline by time by treatment, and strata by time by treatment in the model. Strata were defined by joint levels of HbA1c level (\<= \[less than or equal to\] 8.0% ,\> \[greater than\] 8.0%). Variance-covariance structure for change from baseline was unstructured.
Time frame: Baseline, Week 40
Change From Baseline in HbA1c [Superiority Analysis]
* HbA1c is the glycosylated fraction of hemoglobin A, measured to reflect average plasma glucose concentration over a prolonged period of time. * Values represented under "Least Squares (LS) Mean" are MBE of the unconditional average treatment effect. MBE were calculated using MMRM analysis for post-baseline measures, with country, baseline by time by treatment, and strata by time by treatment in the model. Strata were defined by joint levels of HbA1c level (\<=8.0%, \>8.0%). Variance-covariance structure for change from baseline was unstructured.
Time frame: Baseline, Week 40
Percentage of Participants With an HbA1c Target Value of < 7.0% (53 mmol/Mol)
Percentage of participants with an HbA1c target value of less than (\<) 7.0% (53 millimoles per mole \[mmol/mol\]) was analyzed using a logistic regression model with analysis country, treatment by baseline and treatment by strata in the model. Strata were defined by baseline HbA1c levels (\<=8.0% and \>8.0%). Missing Week 40 data were imputed using a multiple imputation method.
Time frame: Week 40
Percentage of Participants With an HbA1c Target Value of ≤6.5% (48 mmol/Mol)
Percentage of participants with an HbA1c target value of less than or equal to (≤) 6.5% (48 mmol/mol) was analyzed by logistic regression model with analysis country, treatment by baseline and treatment by strata in the model. Strata were defined by baseline HbA1c levels (\<=8.0% and \>8.0%). Missing Week 40 data were imputed using a multiple imputation method.
Time frame: Week 40
Percent Change From Baseline in Body Weight
Values represented under "Least Squares (LS) Mean" are MBE of the unconditional average treatment effect. MBE were calculated using MMRM analysis for post-baseline measures, with country, baseline by time by treatment, and strata by time by treatment in the model. Strata were defined by joint levels of HbA1c level (\<=8.0%, \>8.0%). Variance-covariance structure for change from baseline was unstructured.
Time frame: Baseline, Week 40
Change From Baseline in Body Weight
Values represented under "Least Squares (LS) Mean" are MBE of the unconditional average treatment effect. MBE were calculated using MMRM analysis for post-baseline measures, with country, baseline by time by treatment, and strata by time by treatment in the model. Strata were defined by joint levels of HbA1c level (\<=8.0%, \>8.0%). Variance-covariance structure for change from baseline was unstructured.
Time frame: Baseline, Week 40
Percent Change From Baseline in Non-High-Density Lipoprotein (Non-HDL) Cholesterol
Values represented under "Geometric LS Mean" are MBE of the unconditional average treatment effect. MBE were calculated using MMRM analysis for post-baseline measures: log (actual measurement/baseline) = country, log (baseline) by time by treatment, and strata by time by treatment in the model. Strata were defined by joint levels of HbA1c level (\<=8.0%, \>8.0%). Variance-covariance structure for change from baseline was unstructured.
Time frame: Baseline, Week 40
Percent Change From Baseline in Triglycerides
Values represented under "Geometric LS Mean" are MBE of the unconditional average treatment effect. MBE were calculated using MMRM analysis for post-baseline measures: log (actual measurement/baseline) = country, log (baseline) by time by treatment, and strata by time by treatment in the model. Strata were defined by joint levels of HbA1c level (\<=8.0%, \>8.0%). Variance-covariance structure for change from baseline was unstructured.
Time frame: Baseline, Week 40
Change From Baseline in Systolic Blood Pressure (SBP)
Values represented under "Least Squares (LS) Mean" are MBE of the unconditional average treatment effect. MBE were calculated using MMRM analysis for post-baseline measures, with country, baseline by time by treatment, and strata by time by treatment in the model. Strata were defined by joint levels of HbA1c level (\<=8.0%, \>8.0%). Variance-covariance structure for change from baseline was unstructured.
Time frame: Baseline, Week 40
Change From Baseline in Fasting Serum Glucose (FSG)
Values represented under "Least Squares (LS) Mean" are MBE of the unconditional average treatment effect. MBE were calculated using MMRM analysis for post-baseline measures, with country, baseline by time by treatment, and strata by time by treatment in the model. Strata were defined by joint levels of HbA1c level (\<=8.0%, \>8.0%). Variance-covariance structure for change from baseline was unstructured.
Time frame: Baseline, Week 40
Percentage of Participants With ≥ 5% Body Weight Reduction
Percentage of participants with greater than or equal to (≥) 5% body weight reduction was analyzed by logistic regression model with analysis country, treatment by baseline and treatment by strata in the model. Strata were defined by baseline HbA1c levels (\<=8.0% and \>8.0%). Missing Week 40 data were imputed using a multiple imputation method.
Time frame: Week 40
Percentage of Participants With ≥ 10% Body Weight Reduction
Percentage of participants with ≥ 10% body weight reduction was analyzed by logistic regression model with analysis country, treatment by baseline and treatment by strata in the model. Strata were defined by baseline HbA1c levels (\<=8.0% and \>8.0%). Missing Week 40 data were imputed using a multiple imputation method.
Time frame: Week 40
Percentage of Participants With ≥ 15% Body Weight Reduction
Percentage of participants with ≥ 15% body weight reduction was analyzed by logistic regression model with analysis country, treatment by baseline and treatment by strata in the model. Strata were defined by baseline HbA1c levels (\<=8.0% and \>8.0%). Missing Week 40 data were imputed using a multiple imputation method.
Time frame: Week 40
Change From Baseline in Diastolic Blood Pressure (DBP)
Values represented under "Least Squares (LS) Mean" are MBE of the unconditional average treatment effect. MBE were calculated using MMRM analysis for post-baseline measures, with country, baseline by time by treatment, and strata by time by treatment in the model. Strata were defined by joint levels of HbA1c level (\<=8.0%, \>8.0%). Variance-covariance structure for change from baseline was unstructured.
Time frame: Baseline, Week 40
Percent Change From Baseline in Total Cholesterol
Values represented under "Geometric LS Mean" are MBE of the unconditional average treatment effect. MBE were calculated using MMRM analysis for post-baseline measures: log (actual measurement/baseline) = country, log (baseline) by time by treatment, and strata by time by treatment in the model. Strata were defined by joint levels of HbA1c level (\<=8.0%, \>8.0%). Variance-covariance structure for change from baseline was unstructured.
Time frame: Baseline, Week 40
Change From Baseline in Short Form-36 Health Survey Version 2 (SF-36v2) Acute Form (Physical-Component and Mental-Component) Scores
The SF-36v2 is a participant-reported measure designed to assess health status using 36 items across 8 domains: Physical Functioning, Role-Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role-Emotional, and Mental Health. The physical functioning domain assesses limitations due to health "now," whereas the remaining domains assess functioning "in the past week." Each domain is scored individually, and information from these 8 domains is aggregated into 2 health component summary scores, the Physical Component Summary and Mental Component Summary. Items are answered on Likert scales of varying lengths (3-point, 5-point, or 6-point scales). Scoring of each domain and both summary scores are norm based and presented in the form of T-scores, with a mean of 50 and a standard deviation of 10. Higher scores indicate better levels of function and/or better health. Range cannot be specified in norm-based scores.
Time frame: Baseline, Week 40
Diabetes Treatment Satisfaction Questionnaire-Change Version (DTSQc): Total Score of Treatment Satisfaction
The DTSQc assesses relative change in participant satisfaction with diabetes treatment compared to previous treatment. The questionnaire consists of 8 items, of which 6 items were used to calculate the Total Score of Treatment Satisfaction, covering the following:1. satisfaction with current treatment; 2. convenience of treatment; 3. flexibility; 4. satisfaction with understanding of diabetes; 5. likelihood to recommend present treatment; and 6. satisfaction to continue present treatment. Each item is rated on a 7-point Likert scale from -3 (much less satisfied) to +3 (much more satisfied). Scores from these 6 items are summed to produce the Total Score of Treatment Satisfaction, ranging from -18 (much less satisfied) to +18 (much more satisfied). The higher the score, the greater the improvement in satisfaction with treatment; the lower the score, the greater the deterioration in satisfaction with treatment.
Time frame: Week 40
| Milestone | Orforglipron 3 mg | Orforglipron 12 mg | Orforglipron 36 mg | Dapagliflozin 10 mg |
|---|---|---|---|---|
| Started | 240 | 241 | 241 | 240 |
| Received at least one dose of study drug | 240 | 241 | 241 | 240 |
| Completed | 230 | 225 | 225 | 231 |
| Not completed | 10 | 16 | 16 | 9 |
| Withdrew: Withdrawal by subject | 4 | 8 | 6 | 6 |
| Withdrew: Lost to follow-up | 3 | 5 | 3 | 2 |
| Withdrew: Adverse event | 3 | 3 | 6 | 0 |
| Withdrew: Death | 0 | 0 | 0 | 1 |
| Withdrew: Non-compliance with study drug | 0 | 0 | 1 | 0 |
* Hemoglobin A1c (HbA1c) is the glycosylated fraction of hemoglobin A, measured to reflect average plasma glucose concentration over a prolonged period of time. * Values represented under "Least Squares (LS) Mean" are model-based estimates (MBE) of the unconditional average treatment effect. MBE were calculated using a mixed-model repeated measures (MMRM) analysis for post-baseline measures, with country, baseline by time by treatment, and strata by time by treatment in the model. Strata were defined by joint levels of HbA1c level (\<= \[less than or equal to\] 8.0% ,\> \[greater than\] 8.0%). Variance-covariance structure for change from baseline was unstructured.
| percentage of HbA1c | Orforglipron 3 mg | Orforglipron 12 mg | Orforglipron 36 mg | Dapagliflozin 10 mg |
|---|---|---|---|---|
| Change From Baseline in HbA1c [Noninferiority Analysis] | -1.32 ± 0.074 | -1.74 ± 0.062 | -1.73 ± 0.079 | -0.76 ± 0.076 |
* HbA1c is the glycosylated fraction of hemoglobin A, measured to reflect average plasma glucose concentration over a prolonged period of time. * Values represented under "Least Squares (LS) Mean" are MBE of the unconditional average treatment effect. MBE were calculated using MMRM analysis for post-baseline measures, with country, baseline by time by treatment, and strata by time by treatment in the model. Strata were defined by joint levels of HbA1c level (\<=8.0%, \>8.0%). Variance-covariance structure for change from baseline was unstructured.
| percentage of HbA1c | Orforglipron 3 mg | Orforglipron 12 mg | Orforglipron 36 mg | Dapagliflozin 10 mg |
|---|---|---|---|---|
| Change From Baseline in HbA1c [Superiority Analysis] | -1.32 ± 0.074 | -1.74 ± 0.062 | -1.73 ± 0.079 | -0.76 ± 0.076 |
Percentage of participants with an HbA1c target value of less than (\<) 7.0% (53 millimoles per mole \[mmol/mol\]) was analyzed using a logistic regression model with analysis country, treatment by baseline and treatment by strata in the model. Strata were defined by baseline HbA1c levels (\<=8.0% and \>8.0%). Missing Week 40 data were imputed using a multiple imputation method.
| percentage of participants | Orforglipron 3 mg | Orforglipron 12 mg | Orforglipron 36 mg | Dapagliflozin 10 mg |
|---|---|---|---|---|
| Percentage of Participants With an HbA1c Target Value of < 7.0% (53 mmol/Mol) | 63.25 | 80.09 | 77.94 | 37.03 |
Percentage of participants with an HbA1c target value of less than or equal to (≤) 6.5% (48 mmol/mol) was analyzed by logistic regression model with analysis country, treatment by baseline and treatment by strata in the model. Strata were defined by baseline HbA1c levels (\<=8.0% and \>8.0%). Missing Week 40 data were imputed using a multiple imputation method.
| percentage of participants | Orforglipron 3 mg | Orforglipron 12 mg | Orforglipron 36 mg | Dapagliflozin 10 mg |
|---|---|---|---|---|
| Percentage of Participants With an HbA1c Target Value of ≤6.5% (48 mmol/Mol) | 54.62 | 66.69 | 68.62 | 21.59 |
Values represented under "Least Squares (LS) Mean" are MBE of the unconditional average treatment effect. MBE were calculated using MMRM analysis for post-baseline measures, with country, baseline by time by treatment, and strata by time by treatment in the model. Strata were defined by joint levels of HbA1c level (\<=8.0%, \>8.0%). Variance-covariance structure for change from baseline was unstructured.
| percent change | Orforglipron 3 mg | Orforglipron 12 mg | Orforglipron 36 mg | Dapagliflozin 10 mg |
|---|---|---|---|---|
| Percent Change From Baseline in Body Weight | -3.5 ± 0.38 | -6.3 ± 0.40 | -7.3 ± 0.49 | -3.0 ± 0.27 |
Values represented under "Least Squares (LS) Mean" are MBE of the unconditional average treatment effect. MBE were calculated using MMRM analysis for post-baseline measures, with country, baseline by time by treatment, and strata by time by treatment in the model. Strata were defined by joint levels of HbA1c level (\<=8.0%, \>8.0%). Variance-covariance structure for change from baseline was unstructured.
| kilogram (kg) | Orforglipron 3 mg | Orforglipron 12 mg | Orforglipron 36 mg | Dapagliflozin 10 mg |
|---|---|---|---|---|
| Change From Baseline in Body Weight | -3.2 ± 0.33 | -5.8 ± 0.37 | -6.8 ± 0.46 | -2.7 ± 0.25 |
Values represented under "Geometric LS Mean" are MBE of the unconditional average treatment effect. MBE were calculated using MMRM analysis for post-baseline measures: log (actual measurement/baseline) = country, log (baseline) by time by treatment, and strata by time by treatment in the model. Strata were defined by joint levels of HbA1c level (\<=8.0%, \>8.0%). Variance-covariance structure for change from baseline was unstructured.
| percent change | Orforglipron 3 mg | Orforglipron 12 mg | Orforglipron 36 mg | Dapagliflozin 10 mg |
|---|---|---|---|---|
| Percent Change From Baseline in Non-High-Density Lipoprotein (Non-HDL) Cholesterol | -2.80 ± 1.634 | -8.17 ± 1.597 | -4.99 ± 1.774 | 0.06 ± 1.766 |
Values represented under "Geometric LS Mean" are MBE of the unconditional average treatment effect. MBE were calculated using MMRM analysis for post-baseline measures: log (actual measurement/baseline) = country, log (baseline) by time by treatment, and strata by time by treatment in the model. Strata were defined by joint levels of HbA1c level (\<=8.0%, \>8.0%). Variance-covariance structure for change from baseline was unstructured.
| percent change | Orforglipron 3 mg | Orforglipron 12 mg | Orforglipron 36 mg | Dapagliflozin 10 mg |
|---|---|---|---|---|
| Percent Change From Baseline in Triglycerides | -9.87 ± 2.499 | -12.74 ± 2.704 | -14.76 ± 2.447 | -4.00 ± 2.594 |
Values represented under "Least Squares (LS) Mean" are MBE of the unconditional average treatment effect. MBE were calculated using MMRM analysis for post-baseline measures, with country, baseline by time by treatment, and strata by time by treatment in the model. Strata were defined by joint levels of HbA1c level (\<=8.0%, \>8.0%). Variance-covariance structure for change from baseline was unstructured.
| millimeters of mercury (mmHg) | Orforglipron 3 mg | Orforglipron 12 mg | Orforglipron 36 mg | Dapagliflozin 10 mg |
|---|---|---|---|---|
| Change From Baseline in Systolic Blood Pressure (SBP) | -2.8 ± 0.65 | -5.1 ± 0.69 | -5.8 ± 0.68 | -3.8 ± 0.59 |
Values represented under "Least Squares (LS) Mean" are MBE of the unconditional average treatment effect. MBE were calculated using MMRM analysis for post-baseline measures, with country, baseline by time by treatment, and strata by time by treatment in the model. Strata were defined by joint levels of HbA1c level (\<=8.0%, \>8.0%). Variance-covariance structure for change from baseline was unstructured.
| milligram per deciliter (mg/dL) | Orforglipron 3 mg | Orforglipron 12 mg | Orforglipron 36 mg | Dapagliflozin 10 mg |
|---|---|---|---|---|
| Change From Baseline in Fasting Serum Glucose (FSG) | -32.3 ± 2.55 | -43.1 ± 2.39 | -43.9 ± 2.44 | -22.5 ± 2.91 |
Percentage of participants with greater than or equal to (≥) 5% body weight reduction was analyzed by logistic regression model with analysis country, treatment by baseline and treatment by strata in the model. Strata were defined by baseline HbA1c levels (\<=8.0% and \>8.0%). Missing Week 40 data were imputed using a multiple imputation method.
| percentage of participants | Orforglipron 3 mg | Orforglipron 12 mg | Orforglipron 36 mg | Dapagliflozin 10 mg |
|---|---|---|---|---|
| Percentage of Participants With ≥ 5% Body Weight Reduction | 38.57 | 55.89 | 61.26 | 27.91 |
Percentage of participants with ≥ 10% body weight reduction was analyzed by logistic regression model with analysis country, treatment by baseline and treatment by strata in the model. Strata were defined by baseline HbA1c levels (\<=8.0% and \>8.0%). Missing Week 40 data were imputed using a multiple imputation method.
| percentage of participants | Orforglipron 3 mg | Orforglipron 12 mg | Orforglipron 36 mg | Dapagliflozin 10 mg |
|---|---|---|---|---|
| Percentage of Participants With ≥ 10% Body Weight Reduction | 14.15 | 29.74 | 33.60 | 5.68 |
Percentage of participants with ≥ 15% body weight reduction was analyzed by logistic regression model with analysis country, treatment by baseline and treatment by strata in the model. Strata were defined by baseline HbA1c levels (\<=8.0% and \>8.0%). Missing Week 40 data were imputed using a multiple imputation method.
| percentage of participants | Orforglipron 3 mg | Orforglipron 12 mg | Orforglipron 36 mg | Dapagliflozin 10 mg |
|---|---|---|---|---|
| Percentage of Participants With ≥ 15% Body Weight Reduction | 3.18 | 8.93 | 17.46 | 1.06 |
Values represented under "Least Squares (LS) Mean" are MBE of the unconditional average treatment effect. MBE were calculated using MMRM analysis for post-baseline measures, with country, baseline by time by treatment, and strata by time by treatment in the model. Strata were defined by joint levels of HbA1c level (\<=8.0%, \>8.0%). Variance-covariance structure for change from baseline was unstructured.
| millimeters of mercury (mmHg) | Orforglipron 3 mg | Orforglipron 12 mg | Orforglipron 36 mg | Dapagliflozin 10 mg |
|---|---|---|---|---|
| Change From Baseline in Diastolic Blood Pressure (DBP) | 0.3 ± 0.49 | -1.4 ± 0.49 | -1.3 ± 0.47 | -1.7 ± 0.39 |
Values represented under "Geometric LS Mean" are MBE of the unconditional average treatment effect. MBE were calculated using MMRM analysis for post-baseline measures: log (actual measurement/baseline) = country, log (baseline) by time by treatment, and strata by time by treatment in the model. Strata were defined by joint levels of HbA1c level (\<=8.0%, \>8.0%). Variance-covariance structure for change from baseline was unstructured.
| percent change | Orforglipron 3 mg | Orforglipron 12 mg | Orforglipron 36 mg | Dapagliflozin 10 mg |
|---|---|---|---|---|
| Percent Change From Baseline in Total Cholesterol | -1.13 ± 1.273 | -5.06 ± 1.177 | -3.13 ± 1.307 | 1.00 ± 1.359 |
The SF-36v2 is a participant-reported measure designed to assess health status using 36 items across 8 domains: Physical Functioning, Role-Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role-Emotional, and Mental Health. The physical functioning domain assesses limitations due to health "now," whereas the remaining domains assess functioning "in the past week." Each domain is scored individually, and information from these 8 domains is aggregated into 2 health component summary scores, the Physical Component Summary and Mental Component Summary. Items are answered on Likert scales of varying lengths (3-point, 5-point, or 6-point scales). Scoring of each domain and both summary scores are norm based and presented in the form of T-scores, with a mean of 50 and a standard deviation of 10. Higher scores indicate better levels of function and/or better health. Range cannot be specified in norm-based scores.
| T-score | Orforglipron 3 mg | Orforglipron 12 mg | Orforglipron 36 mg | Dapagliflozin 10 mg |
|---|---|---|---|---|
| Physical Component Score | 2.99 ± 0.473 | 3.06 ± 0.434 | 2.62 ± 0.443 | 2.26 ± 0.442 |
| Mental Component Score | 0.71 ± 0.561 | 0.44 ± 0.458 | 1.10 ± 0.555 | 0.57 ± 0.478 |
The DTSQc assesses relative change in participant satisfaction with diabetes treatment compared to previous treatment. The questionnaire consists of 8 items, of which 6 items were used to calculate the Total Score of Treatment Satisfaction, covering the following:1. satisfaction with current treatment; 2. convenience of treatment; 3. flexibility; 4. satisfaction with understanding of diabetes; 5. likelihood to recommend present treatment; and 6. satisfaction to continue present treatment. Each item is rated on a 7-point Likert scale from -3 (much less satisfied) to +3 (much more satisfied). Scores from these 6 items are summed to produce the Total Score of Treatment Satisfaction, ranging from -18 (much less satisfied) to +18 (much more satisfied). The higher the score, the greater the improvement in satisfaction with treatment; the lower the score, the greater the deterioration in satisfaction with treatment.
| score on a scale | Orforglipron 3 mg | Orforglipron 12 mg | Orforglipron 36 mg | Dapagliflozin 10 mg |
|---|---|---|---|---|
| Diabetes Treatment Satisfaction Questionnaire-Change Version (DTSQc): Total Score of Treatment Satisfaction | 15.28 ± 0.444 | 15.04 ± 0.516 | 15.33 ± 0.615 | 15.22 ± 0.357 |
Collected over Baseline Up to Week 42. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Orforglipron 3 mg | 0/240 (0%) | 8/240 (3.3%) | 174/240 (72.5%) |
| Orforglipron 12 mg | 0/241 (0%) | 14/241 (5.8%) | 180/241 (74.7%) |
| Orforglipron 36 mg | 0/241 (0%) | 10/241 (4.1%) | 180/241 (74.7%) |
| Dapagliflozin 10 mg | 1/240 (0.4%) | 11/240 (4.6%) | 154/240 (64.2%) |
| Event | Orforglipron 3 mg | Orforglipron 12 mg | Orforglipron 36 mg | Dapagliflozin 10 mg |
|---|---|---|---|---|
| Atrial fibrillationCardiac disorders | 0/240 | 1/241 | 0/241 | 2/240 |
| Angina unstableCardiac disorders | 0/240 | 0/241 | 0/241 | 1/240 |
| Arteriosclerosis coronary arteryCardiac disorders | 0/240 | 0/241 | 0/241 | 1/240 |
| Cardiac failure chronicCardiac disorders | 0/240 | 1/241 | 0/241 | 1/240 |
| Coronary artery diseaseCardiac disorders | 0/240 | 1/241 | 0/241 | 1/240 |
| TachyarrhythmiaCardiac disorders | 0/240 | 0/241 | 0/241 | 1/240 |
| VertigoEar and labyrinth disorders | 0/240 | 0/241 | 0/241 | 1/240 |
| Obstructive pancreatitisGastrointestinal disorders | 1/240 | 0/241 | 0/241 | 0/240 |
| Septic shockInfections and infestations | 0/240 | 0/241 | 0/241 | 1/240 |
| Urinary tract infectionInfections and infestations | 1/240 | 0/241 | 0/241 | 0/240 |
| Event | Orforglipron 3 mg | Orforglipron 12 mg | Orforglipron 36 mg | Dapagliflozin 10 mg |
|---|---|---|---|---|
| NauseaGastrointestinal disorders | 47/240 | 43/241 | 54/241 | 4/240 |
| DiarrhoeaGastrointestinal disorders | 44/240 | 40/241 | 48/241 | 12/240 |
| Diabetic retinopathyEye disorders | 29/240 | 30/241 | 27/241 | 37/240 |
| VomitingGastrointestinal disorders | 19/240 | 20/241 | 29/241 | 4/240 |
| ConstipationGastrointestinal disorders | 19/240 | 20/241 | 25/241 | 2/240 |
| DyspepsiaGastrointestinal disorders | 15/240 | 12/241 | 25/241 | 2/240 |
| Abdominal distensionGastrointestinal disorders | 12/240 | 13/241 | 20/241 | 3/240 |
| Decreased appetiteMetabolism and nutrition disorders | 12/240 | 8/241 | 20/241 | 0/240 |
| NasopharyngitisInfections and infestations | 17/240 | 14/241 | 16/241 | 10/240 |
| HyperglycaemiaMetabolism and nutrition disorders | 14/240 | 6/241 | 3/241 | 15/240 |
All randomized participants.
| Age, Continuous(years) | Orforglipron 3 mg | Orforglipron 12 mg | Orforglipron 36 mg | Dapagliflozin 10 mg | Total |
|---|---|---|---|---|---|
| Mean | 55.1 ± 11.8 | 55.9 ± 11.6 | 56.6 ± 11.5 | 56.6 ± 11.1 | 56.1 ± 11.5 |
| Sex: Female, Male(Participants) | Orforglipron 3 mg | Orforglipron 12 mg | Orforglipron 36 mg | Dapagliflozin 10 mg | Total |
|---|---|---|---|---|---|
| Female | 117 | 121 | 123 | 113 | 474 |
| Male | 123 | 120 | 118 | 127 | 488 |
| Ethnicity (NIH/OMB)(Participants) | Orforglipron 3 mg | Orforglipron 12 mg | Orforglipron 36 mg | Dapagliflozin 10 mg | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 114 | 114 | 116 | 114 | 458 |
| Not Hispanic or Latino | 124 | 125 | 122 | 124 | 495 |
| Unknown or Not Reported | 2 | 2 | 3 | 2 | 9 |
| Race (NIH/OMB)(Participants) | Orforglipron 3 mg | Orforglipron 12 mg | Orforglipron 36 mg | Dapagliflozin 10 mg | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 67 | 62 | 53 | 61 | 243 |
| Asian | 43 | 42 | 44 | 42 | 171 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 6 | 6 | 2 | 6 | 20 |
| White | 119 | 125 | 131 | 125 | 500 |
| More than one race | 5 | 5 | 11 | 6 | 27 |
| Unknown or Not Reported | 0 | 1 | 0 | 0 | 1 |
| Region of Enrollment(Participants) | Orforglipron 3 mg | Orforglipron 12 mg | Orforglipron 36 mg | Dapagliflozin 10 mg | Total |
|---|---|---|---|---|---|
| China | 25 | 26 | 25 | 26 | 102 |
| Germany | 30 | 29 | 29 | 29 | 117 |
| Mexico | 99 | 100 | 100 | 100 | 399 |
| Poland | 36 | 36 | 36 | 35 | 143 |
| Taiwan | 15 | 15 | 15 | 15 | 60 |
| United States | 35 | 35 | 36 | 35 | 141 |
| HemoglobinA1c (HbA1c)(Percentage of HbA1c) | Orforglipron 3 mg | Orforglipron 12 mg | Orforglipron 36 mg | Dapagliflozin 10 mg | Total |
|---|---|---|---|---|---|
| Mean | 8.17 ± 1.08 | 8.11 ± 1.05 | 8.18 ± 1.08 | 8.09 ± 0.98 | 8.14 ± 1.04 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Anonymized individual participant level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting.
Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Data sharing details ↗ · vivli.org
Ran from Jan 2024 to primary completion in Sep 2025, 20 months.
Results were first posted in Oct 2026, 1 year after primary completion.
Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 20 months is close to that.
Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Orforglipron